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Edited by Varda RotterAbstract Cip/Kip family protein p21, a cyclin-dependent kinase
(CDK) inhibitor, is directly transactivated by retinoic acid recep-
tor alpha (RARa) upon retinoic acid (RA):RARa binding. Yet
the role of p21 upregulation by RA in lymphoma cells remains
unknown. Here, we show that, in human pre-B lymphoma Nalm6
cells, RA-induced proliferation inhibition results from massive
cell death characterized by apoptosis. Upregulated p21 by RA
accompanies caspase-3 activation and precedes the occurrence
of apoptosis. p21 induction leads to increased p21 complex for-
mation with cyclin E/CDK2, which occurs when cyclin E and
CDK2 levels remain constant. CDK2 can alternatively promote
apoptosis, but the mechanisms remain unknown. Data presented
here suggest a novel RA-signaling, by which RA-induced p21
induction and complex formation with cyclin E/CDK2 diverts
CDK2 function from normally driving proliferation to alterna-
tively promoting apoptosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Retinoid; Apoptosis; p21 induction; CDK2 activity;
p21–CDK2 interaction1. Introduction
RA is a potential inducer of leukemia cell diﬀerentiation and
apoptosis [1,2]. By acting as a ligand for signaling events, RA
exerts its eﬀect by binding to nuclear receptor RAR isotypes
(a, b, and c) and retinoid X receptor (RXR) isotypes (a, b,
and c) [3]. Liganded RARs and RXRs act as heterodimers
[4] to induce expression of target genes at the retinoic acid
responsive element (RARE) of their promoters [5]. In the pres-
ence of RA, the eﬀects of RARa are also mediated by phos-
phorylation-modiﬁcation [6–8] and ubiquitination-proteolysis
[9,10]. Currently, the molecular bases of these distinguished
pathways mediated by RA remain largely unknown.Abbreviations: CDK, cyclin-dependent kinase; RA, retinoic acid;
RARa, retinoic acid receptor alpha; RARE, retinoic acid responsive
element; ATRA, all-trans retinoic acid
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doi:10.1016/j.febslet.2006.05.052To date, p21 is the only known cell cycle gene that is di-
rectly transactivated by liganded RARa via RARE of the
p21 promoter [11]. Growing studies show that p21 is a posi-
tive regulator of cyclin D/CDK4 activity but an inhibitor of
cyclin E/CDK2 activity [12,13]. Although the interaction be-
tween p21 and the cyclin E/CDK2 complex commonly leads
to the suppression of CDK2 activity [14–19], two diﬀerent
forms of p21 interaction with cyclin E/CDK2 can lead to
two functionally distinct outcomes: one in which CDK2 activ-
ity is inhibited and the other in which CDK2 remains active
[19]. Speciﬁcally, cyclin E/CDK2 complex interaction with
both the cyclin and the CDK2 binding sites on p21 leads to
inhibition of CDK2 kinase activity, whereas cyclin E/CDK2
complex interaction with either the cyclin or the CDK2 bind-
ing site on p21 (but not with both) does not lead to inhibition
of CDK2 kinase activity [19]. CDK2 activity normally drives
cell proliferation by mediating cell cycle G1/S transition.
However, many studies have demonstrated that CDK2 activ-
ity is also important for promoting many forms of apoptosis
[20,21]. The molecular mechanisms that determine whether
CDK2 activity drives cell cycle progression or promotes cell
death remain unknown.
Human acute lympholastic leukemia derived from B cells is
divided into four major stages, which include pro-B, pre-B,
immature, and mature lymphomas. While the molecular mech-
anisms and biochemical pathways by which RA mediates mye-
loid leukemia cell diﬀerentiation and apoptosis have been
actively approached in the past two decades [2,22], the possible
anti-proliferation eﬃcacy of RA in B-cell lymphomas has been
scarcely studied [23,24]. To explore the role of RA against can-
cer in lymphoma cells, we investigated the eﬀects of all-trans
retinoic acid (ATRA) in mediating antiproliferative responses
in pre-B lymphoma Nalm6 cells. Our studies show that ATRA
inhibits proliferation by inducing apoptosis in Nalm6 cells,
and that the eﬀect of ATRA:RARa binding on apoptosis
may be mediated by p21 induction and interaction with the cy-
clin E/CDK2 complex.2. Materials and methods
2.1. Cell culture
Human pre-B lymphoma Nalm6 cells were cultured in RPMI 1640
medium [25] supplemented with either 10%, 5%, or 2% FBS at 37 C
in a moist atmosphere of 5% CO2. ATRA and 9-cis-RA (9cRA) were
purchased from Sigma (St. Louis, MO).blished by Elsevier B.V. All rights reserved.
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Cell proliferation was determined by cell counting. Equal numbers
of cells were plated onto 6-well plates in triplicate. Twenty-four hours
after plating, the cells were counted for up to 9 days. Using trypan blue
exclusion methodology, the degree of cell death associated with cell
proliferation in the cultures was simultaneously measured.
2.3. Assessment of nuclear apoptotic morphologies
Apoptotic morphologic changes in nuclei of Nalm6 cells were deter-
mined with propidium iodide (PI) stain as described [26]. In brief, the
cells were ﬁxed in 4% paraformaldehyde and permeabilized in 0.1%
Triton X-100/0.1% sodium citrate. Cell nuclei were stained with PI
in aqueous mounting medium. The slides were viewed with a Leica
ﬂuorescence microscope, and the images were acquired using SD-
300/VDS-1400 SKY camera. Digital adjustments of ﬂuorescence
images were performed using Adobe Photoshop.
2.4. In situ detection of DNA strand breaks in apoptotic cells
In situ DNA fragmentation was detected by end-labeling free 3 0OH
DNA using terminal transferase (TdT)-mediated dUTP Nick End
Labeling (TUNEL) kit (Roche Applied Science, Indianapolis) follow-
ing manufacturer’s instructions. Brieﬂy, TUNEL assay was performed
by incubating the cells with reaction mixture containing TdT and ﬂuo-
rescein-dUTP in a humidiﬁed chamber for 1 h at 37 C. Negative con-
trols were incubated with reaction mixtures lacking-TdT. The slides
were washed with PBS and the nuclei were stained with PI in aqueous
mounting medium. The slides were viewed with a Leica ﬂuorescence
microscope, and the images were acquired using SD-300/VDS-1400
SKY camera. Identical exposure times were used in capturing images
for each ﬂuorophore in all cells in each experiment. Digital adjust-
ments of ﬂuorescence images were performed using Adobe Photoshop.
2.5. Western blotting
Western blotting was performed as described [27]. Enhanced chemi-
luminescence (Applied Biosystems, Foster City, CA) was used for
detection of immunoreactive proteins using appropriate secondary
anti-IgG alkaline phosphatase conjugates (Sigma) as recommended
by the manufacturer. Polyclonal rabbit anti-active subunit of cas-
pase-3 antibody was purchased from BD biosciences (San Jose, CA).
All other antibodies used in immunoblotting were from Santa Cruz
Biotechnology (Santa Cruz, CA).
2.6. Immunoprecipitation
Immunoprecipitation was performed as described before [28]. Poly-
clonal anti-p21 antibody was purchased from Santa Cruz Biotechnol-
ogy. The cells were lysed using universal lysis/immunoprecipitation
(ULI) buﬀer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 2 mM
EGTA, 25 mM NaFl, 25 mM b-glycerophosphate [pH 7.5], 0.1 mM
sodium orthovanadate, 0.1 mM PMSF, 5 lg of leupeptin per ml,
0.2% [vol/vol] Triton X-100, 0.5% [vol/vol] Nonidet P-40). Proteins
were pre-cleaned with normal IgG. Complexed-precipitates were
washed with ULI buﬀer and separated on SDS–PAGE. The resulting
blot was analyzed by Western blotting with diﬀerent antibodies.Fig. 1. ATRA inhibits proliferation by inducing cell death. (A) and (B) Th
showed similar proliferation capacity in the presence of either 5% or 2% FBS
(C) Massive cell death was induced by ATRA in the presence of 2% FBS.3. Results
3.1. ATRA inhibits proliferation by inducing cell death
To explore the antiproliferative eﬀect of ATRA on pre-B
lymphomas, Nalm6 cells were exposed to ATRA (5 lM) or
9cRA (5 lM) in the presence of 10% FBS. The results showed
that, in the presence of 10% FBS, ATRA treatment only
slightly inhibited cell proliferation while 9cRA treatment pro-
duced no observable eﬀect (data not shown). Because in some
cancer cell lines proliferation can be inhibited only in low ser-
um cell culture conditions [8,29–31], we then tested whether
ATRA inhibited Nalm6 cell proliferation in the presence of
either 5% or 2% FBS. We found that, while Nalm6 cells
showed a similar proliferation capacity in the cultures contain-
ing either 5% or 2% FBS, ATRA inhibited cell proliferation
only in the presence of 2% FBS (Fig. 1A vs. B). By using try-
pan blue staining to measure cell viability associated with cell
proliferation, we found that proliferation inhibition by ATRA
in 2% serum was associated with massive cell death after cul-
turing cells for 5 days (Fig. 1C). These results show that
ATRA-induced proliferation inhibition results from cell death
when serum factor(s) is limited in Nalm6 cells.
3.2. ATRA induces apoptotic cell death
To determine whether ATRA-induced cell death results
from apoptosis, we used PI stain to examine apoptotic mor-
phologic changes in the nuclei of Nalm6 cells. The results
showed typical features of apoptosis in the cells exposed to
ATRA, including chromatin condensation, DNA fragmenta-
tion, and nuclear membrane breakdown (Fig. 2A). To further
determine whether this morphologically recognizable cell
death is implemented by a mechanism of apoptosis, we deter-
mined caspase-3 activation since caspase-3 is a known apopto-
tic executioner. By using an anti-active form of caspase-3
polyclonal antibody that speciﬁcally recognizes the 18 kDa ac-
tive subunit of human caspase-3 in Western analysis, we found
that the active subunit of caspase-3 was upregulated after 72 h
of ATRA treatment (Fig. 2B). This upregulation of caspase-3
active subunit is followed by ATRA-induced massive cell
death (Figs. 1C and 2B). Together, these results indicate that
ATRA induces an antiproliferative response via apoptosis in
Nalm6 cells.
Cleavage of chromosomal DNA into oligonucleosomal units
is a hallmark of apoptosis [32,33]. To conﬁrm that ATRA-in-
duced cell death indeed results from a mechanism of apoptosis,e data represent the mean S.D. of triplicate wells. While Nalm6 cells
, proliferation was only inhibited by ATRA in the presence of 2% FBS.
Fig. 2. ATRA induces apoptotic cell death. (A) ATRA induced an apoptotic morphologic change in the nuclei of Nalm6 cells exposed to ATRA for
5 days. (B) The active subunit of caspase-3 was induced after 72 h of ATRA treatment. Actin was used as a loading control. WB, Western blotting;
Caspase-3AS, active subunit of caspase-3. (C) Apoptotic cell death was determined by TUNEL assay.
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breaks in individual cells exposed to ATRA. Because massive
cell death occurred after 5 days of ATRA treatment (Figs.
1B, C, and 2A), we cultured Nalm6 cells in the presence or ab-
sence of ATRA for 5, 7, and 9 days. The free 3 0OH ends in
genomic DNA were labeled with FITC-dUTP and assessed un-
der a ﬂuorescence microscope. In Nalm6 cells without ATRA
treatment, PI staining was observed evenly among the nuclei
(Fig. 2C, panels 1, 7, and 13). Correspondingly, no DNA
breaks were positively labeled with FITC-dUTP (Fig. 2C, pan-
els 2, 8, and 14). Co-localizing PI stained nuclei and FITC-
dUTP labeled nuclei revealed a normal nuclear morphology
(Fig. 2C, panels 3, 9, and 15). In contrast, DNA fragmenta-
tions were readily identiﬁed in ATRA-treated cells (Fig. 2C,
panels 6, 12, and 18) by co-localizing PI stained nuclei
(Fig. 2C, panels 4, 10, and 16) and FITC-dUTP labeled nucleiFig. 3. ATRA-induced RARa degradation precedes p21 induction in Nalm6
ATRA upregulated p21 expression. (C) p53 levels remained unchanged in th(Fig. 2C, panels 5, 11, and 17). Hence, these in situ data dem-
onstrate that ATRA inhibits proliferation by inducing apopto-
sis in Nalm6 cells.
3.3. ATRA-induced RARa degradation precedes p21 induction in
Nalm6 cells undergoing apoptosis
The mechanism by which ATRA induces apoptosis in pre-B
lymphoma cells is unknown. We next investigated the molecu-
lar basis of ATRA-action in Nalm6 cell apoptosis. Because
CDK inhibitor p21 is directly transactivated by liganded
RARa [11] while RARa is rapidly degraded upon ATRA
binding [7,10,34,35], we investigated whether RARa degrada-
tion and p21 upregulation are involved in ATRA-induced
Nalm6 cell apoptosis. Using immunoblotting to determine
the protein levels of p21 and RARa, we found that RARa
was degraded rapidly in the presence of ATRA (Fig. 3A).cells undergoing apoptosis. (A) ATRA induced RARa degradation. (B)
e presence of ATRA.
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72 h of ATRA treatment (Fig. 3B). The p21 induction occurs
simultaneously with caspase-3 activation (Fig. 2B), which
was then followed by apoptotic cell death after 120 h of ATRA
treatment (Figs. 1B, C, 2A, and C). Hence, p21 induction upon
ATRA:RARa binding may play an important role in ATRA-
induced Nalm6 cell apoptosis.
p21 is also a well-known transcriptional target of tumor sup-
pressor protein p53 [36], and p53 induction in response to
DNA damage transcriptionally upregulates p21 in order to ar-
rest the cell cycle for DNA repair [37,38]. Because Nalm6 cells
express wild type p53 [39], we investigated whether p21 induc-
tion has any relationship with p53 expression in the presence of
ATRA. By using Western analysis, we found that, in clear con-
trast to RARa reduction and p21 upregulation (Fig. 3A and
B), p53 levels remained unchanged in Nalm6 cells exposed to
ATRA (Fig. 3C). These results suggest that p21 induction
upon ATRA:RARa binding is p53-independent in Nalm6
cells.
3.4. Increased p21 complex formation with cyclin E/CDK2
accompanies Nalm6 cell apoptosis
The known oncogenic function of p21 is to protect cells from
apoptosis in response to non-retinoid stimuli [13,40] by inhib-
iting caspase-3 activation and resisting Fas-mediated cell death
[41,42]. Our above data show that p21 induction (Fig. 3B)
accompanies the expression of caspase-3 active subunit
(Fig. 2B), indicating that ATRA-induced p21 upregulation
does not inhibit caspase-3 activity but instead may modulate
the eﬀect of ATRA on apoptosis. A question that arises is
how p21 induction by ATRA is involved in promoting apop-
tosis. Several lines of study have indicated that CDK2 activa-
tion is important for promoting apoptosis [20,21,43,44].
Importantly, CDK2 can still remain active when p21 interacts
with the cyclin E/CDK2 complex at only one of the two N-ter-
minal binding domains of p21 [19]. Hence, ATRA upregulated
p21 may promote CDK2 activation in mediating apoptosis byFig. 4. Increased p21 complex formation with cyclin E/CDK2 accompanies N
precipitated with anti-p21 antibody. The resulting precipitates were analyze
lysate was used as a positive control in Western blotting (lane 6). PI, pre-
complexed-precipitates was analyzed by immunoblotting as described in (A).
cyclin/CDK4 and cyclin/CDK2 complexes as indicated.interacting with cyclin E/CDK2 in an alternative manner. We
tested this idea by measuring p21-CDK2 association in Nalm6
cells that underwent ATRA-induced apoptosis. Cellular pro-
teins were extracted from Nalm6 cells with or without ATRA
treatment, and the putative p21-CDK2 complexes were precip-
itated by p21 antibody. By analyzing p21 complexed-precipi-
tates using immunoblotting, we found that ATRA promotes
p21 complex formation with cyclin E/CDK2, evidenced by in-
creased cyclin E and CDK2 in the precipitates (Fig. 4A). The
increased p21-CDK2 complex formation accompanied p21
dissociation from cyclin D2, while cyclin A was not detected
in the precipitates (Fig. 4B). These results suggest that
ATRA-induced p21 association with cyclin E/CDK2 and p21
dissociation from cyclin D/CDK complexes is involved in
modulating Nalm6 cell apoptosis.
The primary functions of cyclin/CDK2 and cyclin/CDK4
complexes in cell cycle control are precisely regulated by the
competition between their sequestration and un-sequestration
of p21 [12,13]. To determine the relationship between p21
sequestration and subunit expression of cyclin/CDK com-
plexes during ATRA-induced apoptosis, we assessed the pro-
tein levels of those subunits in Nalm6 cells using Western
analyses. We found that Cip/Kip family protein p27, which
is mainly complexed with cyclin D/CDK [45,46] to stabilize ki-
nase activity [12], was inhibited in the presence of ATRA
(Fig. 4C). Cyclin D1 was undetectable (data not shown)
whereas cyclin D2 expression decreased after 72 h of ATRA
treatment (Fig. 4D). Meanwhile, the protein levels of CDK2,
cyclin E, cyclin A, and CDK4 remained basically unchanged
(Fig. 4D and E). Because p27 stabilizes the cyclin D/CDK
complex and functions as a positive regulator of cyclin D-
dependent kinase [12,13], decreased p27 levels may reﬂect re-
duced cyclin D/CDK complex formation and decreased cyclin
D/CDK activity during ATRA-induced Nalm6 cell apoptosis.
Furthermore, the association between p21 and cyclin D2 was
decreased immediately after 24 h of ATRA treatment
(Fig. 4B, lanes 1 vs. 2) while the total protein levels of cyclinalm6 cell apoptosis. (A) p21 and p21-complexed cyclin E/CDK2 were
d by Western blotting using diﬀerent antibodies as indicated. Nalm6
immune IgG. B, p21 interaction with cyclin D2 and cyclin A in p21
(C–E), Western blotting depicted protein levels of diﬀerent subunits of
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(Fig. 4D). This indicates that p21 dissociation from the cyclin
D2/CDK complex by ATRA is independent of cyclin D2 lev-
els. More importantly, because both increased p21 expression
(Fig. 3B) and complex formation with cyclin E/CDK2
(Fig. 4A) occur when cyclin E and CDK2 levels remain con-
stant (Fig. 4D and E), ATRA-induced p21 upregulation and
increased p21 sequestration of cyclin E/CDK2 may be involved
in diverting CDK2 function to promote apoptosis in Nalm6
cells.Fig. 5. p21 complex formation with cyclin E/CDK2 in regulating
apoptosis and cell cycle. (A) The hypothesized apoptotic pathway
mediated by ATRA-signaling is marked in red. p21 complex formation
with cyclin E/CDK2 may be modulated by a putative co-factor (CF) in
the presence of ATRA. ATRA-induced CF may mediate an alternative
p21 interaction with cyclin E/CDK2 by occupying one of the two N-
terminal binding sites of p21, both of which are normally bound by
cyclin E/CDK2 to inactivate CDK2 kinase activity [19]. This alterna-
tive interaction leads to generating an active cyclin E/CDK2 complex
for promoting apoptosis. (B) A well-known E2F activation pathway
mediated by cyclin D/CDK4 phosphorylation inactivation of pRb
induces cyclin E expression and association with CDK2, leading to G1/
S transition. (C) Competing p21 sequestration between cyclin D/
CDK4 and cyclin E/CDK2. A ternary p21-cyclin D/CDK4 complex
sustains CDK4 kinase activity that is necessary for G1 progression,
while a ternary p21-cyclin E/CDK2 complex is inactive and inhibits
G1/S transition [12].4. Discussion
Previous studies show that p21 prevents apoptosis in re-
sponse to non-retinoid stimuli. Here, we have for the ﬁrst time
presented evidence that p21 upregulation and complex forma-
tion with cyclin E/CDK2 is involved in modulating RA-
induced pre-B lymphoma Nalm6 cell apoptosis.
4.1. RARa reduction leads to p21 induction in RA-induced
apoptosis
RARa is degraded within 6 h in the presence of RA through
proteasome-degradation pathway [7,9,35], which is then fol-
lowed by transactivation of RA-target gene to modulate RA-
signaling events [22,47]. According to the current model of
gene regulation by retinoids [5,48], unliganded and DNA-
bound retinoid receptors repress transcription through the
recruitment of co-repressors at RARE of target genes
[5,22,49,50]. Thus, to activate gene expression, retinoid recep-
tors will have to contend with the repressive chromatin struc-
tures in order to dissociate repressors and to allow the
recruitment of the transcription machinery [5,49,50]. Indeed,
RA treatment decreases RARa levels [7,9,35] and diminishes
the binding of RARa to RARE while it stimulates transactiva-
tion [51,52]. RA upregulates p21 expression [11,53,54] and li-
ganded RARa transactivates p21 via RARE of the p21
promoter [11]. In this study, RARa reduction precedes p21
induction (Fig. 3A vs. B). The occurrence of p21 induction
accompanies caspase-3 activation (Figs. 2B and 3B), which is
followed by massive apoptotic cell death (Figs. 1 and 2). To-
gether, these studies suggest that RARa reduction is involved
in upregulating p21 expression in mediating RA-induced
Nalm6 cell apoptosis.
4.2. Increased complex formation of p21 with cyclin E/CDK2
may modulate RA-induced apoptosis
Many studies have recently established that p21, despite its
primary function in the cell cycle as a negative regulator of
the cyclinE/CDK2 complex and as a positive regulator of cy-
clin D-dependent kinase activity, also regulates apoptosis, cell
migration, and transcription [12,13,38,40]. These functions de-
pend on diﬀerent cellular stimuli and diﬀerent targets, present
either in the cytoplasm, in the nucleus, or on DNA. To date,
p21 upregulation by RA is best documented in mediating mye-
loid diﬀerentiation [55]. We ﬁnd that RA-induced p21 induc-
tion (Fig. 3B) is associated with caspase activation and
apoptotic cell death (Figs. 1 and 2). Such apoptotic cell death
accompanies both increased p21 complex formation with cy-
clin E/CDK2 and decreased p21 association with cyclin D2
(Fig. 4A vs. B). Hence, the result from Nalm6 cells suggest thatp21, instead of preventing apoptosis in response to non-reti-
noid stimuli [13] and instead of modulating diﬀerentiation in
myeloid cells treated with RA [55], is involved in mediating
RA-induced Nalm6 cell apoptosis through its complex forma-
tion with cyclin E/CDK2.
4.3. RA signaling may divert CDK2 to promote apoptosis by
inducing an alternative interaction between p21 and cyclin
E/CDK2
Activation of CDK2 has been observed in many forms of
apoptosis [20,21]. How does CDK2 activity, which normally
drives cell cycle progression, contribute to apoptosis? Previous
studies demonstrate that CDK2 activation/inactivation is pre-
cisely regulated through p21 association/dissociation with the
cyclin E/CDK2 complex [12,13]. Cyclin E/CDK2 complex is
active if it is either free from p21 binding [12] or bound to only
one of the two p21 N-terminal binding sites [19], whereas cy-
clin E/CDK2 complex is inactivated if it interacts with both
of the two p21 N-terminal binding sites [19]. Our studies show
that p21 induction (Fig. 3B) is associated with unchanged lev-
els of total cyclin E and CDK2 in Nalm6 cells treated with RA
(Fig. 4D and E). Such p21 induction results in an increased
sequestration of cyclin E/CDK2, accompanies caspase-3 acti-
vation, and is associated with apoptotic cell death (Figs. 1, 2,
and 4). Thus, p21 might modulate the eﬀect of RA on apopto-
sis by interacting with the cyclin E/CDK2 complex in an alter-
native manner in Nalm6 cells, e.g., binding to the cyclin E/
CDK2 complex via only one of its two binding sites while
simultaneously interacting with a RA-induced co-factor
through its other binding site (Fig. 5).
3692 G.C. Bao et al. / FEBS Letters 580 (2006) 3687–3693There is increasing evidence that p21 and CDK2 are in-
volved in controlling the intricate balance between cell prolif-
eration and cell death. We show that p21 induction and
increased p21 complex formation with cyclin E/CDK2 are in-
volved in RA-induced apoptosis in Nalm6 cells, suggesting
that RA-induced p21 sequestration of cyclin E/CDK2 diverts
CDK2 function from driving proliferation to promoting apop-
tosis. Further evaluating this novel mechanism of RA-action
will advance the ﬁeld of RA-signaling and provide new mech-
anistic strategies against pre-B lymphoma in clinical medicine.
Acknowledgments: This work was supported by a grant from the Mar-
tell Foundation for Cancer Research to A.J. and a federal work-study
award to G.C.B.References
[1] Evans, T. (2005) Regulation of hematopoiesis by retinoid
signaling. Exp. Hematol. 33, 1055–1061.
[2] Altucci, L. and Gronemeyer, H. (2002) Decryption of the retinoid
death code in leukemia. J. Clin. Immunol. 22, 117–123.
[3] Chambon, P. (1996) A decade of molecular biology of retinoic
acid receptors. FASEB J. 10, 940–954.
[4] Kastner, P., Mark, M., Ghyselinck, N., Krezel, W., Dupe, V.,
Grondona, J.M. and Chambon, P. (1997) Genetic evidence that
the retinoid signal is transduced by heterodimeric RXR/RAR
functional units during mouse development. Development 124,
313–326.
[5] Bastien, J. and Rochette-Egly, C. (2004) Nuclear retinoid recep-
tors and the transcription of retinoid-target genes. Gene 328, 1–
16.
[6] Rochette-Egly, C., Adam, S., Rossignol, M., Egly, J.M. and
Chambon, P. (1997) Stimulation of RAR alpha activation
function AF-1 through binding to the general transcription factor
TFIIH and phosphorylation by CDK7. Cell 90, 97–107.
[7] Wang, J., Barsky, L.W., Shum, C.H., Jong, A., Weinberg, K.I.,
Collins, S.J., Triche, T.J. and Wu, L. (2002) Retinoid-induced G1
arrest and diﬀerentiation activation are associated with a switch to
cyclin-dependent kinase-activating kinase hypophosphorylation
of retinoic acid receptor alpha. J. Biol. Chem. 277, 43369–43376.
[8] Zhang, S., He, Q., Peng, H., Tedeschi-Blok, N., Triche, T.J. and
Wu, L. (2004) MAT1-Modulated Cyclin-Dependent Kinase-
Activating Kinase Activity Cross-Regulates Neuroblastoma Cell
G(1) Arrest and Neurite Outgrowth. Cancer Res. 64, 2977–2983.
[9] Zhu, J., Gianni, M., Kopf, E., Honore, N., Chelbi-Alix, M.,
Koken, M., Quignon, F., Rochette-Egly, C. and de The, H. (1999)
Retinoic acid induces proteasome-dependent degradation of
retinoic acid receptor alpha (RARalpha) and oncogenic RARal-
pha fusion proteins. Proc. Natl. Acad. Sci. USA 96, 14807–14812.
[10] He, Q., Peng, H., Collins, S.J., Triche, T.J. and Wu, L. (2004)
Retinoid-modulated MAT1 ubiquitination and CAK activity.
FASEB J. 18, 1734–1736.
[11] Liu, M., Iavarone, A. and Freedman, L.P. (1996) Transcriptional
activation of the human p21(WAF1/CIP1) gene by retinoic acid
receptor. Correlation with retinoid induction of U937 cell
diﬀerentiation. J. Biol. Chem. 271, 31723–31728.
[12] Sherr, C.J. and Roberts, J.M. (1999) CDK inhibitors: positive and
negative regulators of G1-phase progression. Genes Dev. 13,
1501–1512.
[13] Coqueret, O. (2003) New roles for p21 and p27 cell-cycle
inhibitors: a function for each cell compartment? Trends Cell
Biol. 13, 65–70.
[14] Chen, J., Jackson, P.K., Kirschner, M.W. and Dutta, A. (1995)
Separate domains of p21 involved in the inhibition of Cdk kinase
and PCNA. Nature 374, 386–388.
[15] Goubin, F. and Ducommun, B. (1995) Identiﬁcation of binding
domains on the p21Cip1 cyclin-dependent kinase inhibitor.
Oncogene 10, 2281–2287.
[16] Luo, Y., Hurwitz, J. and Massague, J. (1995) Cell-cycle inhibition
by independent CDK and PCNA binding domains in p21Cip1.
Nature 375, 159–161.[17] Warbrick, E., Lane, D.P., Glover, D.M. and Cox, L.S. (1995) A
small peptide inhibitor of DNA replication deﬁnes the site of
interaction between the cyclin-dependent kinase inhibitor
p21WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5,
275–282.
[18] Nakanishi, M., Robetorye, R.S., Adami, G.R., Pereira-Smith,
O.M. and Smith, J.R. (1995) Identiﬁcation of the active region of
the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. EMBO
J. 14, 555–563.
[19] Fotedar, R., Fitzgerald, P., Rousselle, T., Cannella, D., Doree,
M., Messier, H. and Fotedar, A. (1996) p21 contains independent
binding sites for cyclin and cdk2: both sites are required to inhibit
cdk2 kinase activity. Oncogene 12, 2155–2164.
[20] Fotedar, R., Diederich, L. and Fotedar, A. (1996) Apoptosis and
the cell cycle. Prog. Cell Cycle Res. 2, 147–163.
[21] Guo, M. and Hay, B.A. (1999) Cell proliferation and apoptosis.
Curr. Opin. Cell Biol. 11, 745–752.
[22] Melnick, A. and Licht, J.D. (1999) Deconstructing a disease:
RARalpha, its fusion partners, and their roles in the pathogenesis
of acute promyelocytic leukemia. Blood 93, 3167–3215.
[23] Sundaresan, A., Claypool, K., Mehta, K., Lopez-Berestein, G.,
Cabanillas, F. and Ford Jr, R.J. (1997) Retinoid-mediated
inhibition of cell growth with stimulation of apoptosis in
aggressive B-cell lymphomas. Cell Growth Diﬀer. 8, 1071–1082.
[24] Guidoboni, M., Zancai, P., Cariati, R., Rizzo, S., Dal Col, J.,
Pavan, A., Gloghini, A., Spina, M., Cuneo, A., Pomponi, F.,
Bononi, A., Doglioni, C., Maestro, R., Carbone, A., Boiocchi, M.
and Dolcetti, R. (2005) Retinoic acid inhibits the proliferative
response induced by CD40 activation and interleukin-4 in mantle
cell lymphoma. Cancer Res. 65, 587–595.
[25] Leclerc, G.J., Leclerc, G.M. and Barredo, J.C. (2002) Real-time
RT-PCR analysis of mRNA decay: half-life of Beta-actin mRNA
in human leukemia CCRF-CEM and Nalm-6 cell lines. Cancer
Cell Int. 2, 1.
[26] Wu, L., Chen, P., Hwang, J.J., Barsky, L.W., Weinberg, K.I.,
Jong, A. and Starnes, V.A. (1999) RNA antisense abrogation of
MAT1 induces G1 phase arrest and triggers apoptosis in aortic
smooth muscle cells. J. Biol. Chem. 274, 5564–5572.
[27] Wang, B., Feng, L., Hu, Y., Huang, S.H., Reynolds, C.P., Wu, L.
and Jong, A.Y. (1999) The essential role of Saccharomyces
cerevisiae CDC6 nucleotide-binding site in cell growth, DNA
synthesis, and Orc1 association. J. Biol. Chem. 274, 8291–8298.
[28] Elsasser, S., Lou, F., Wang, B., Campbell, J.L. and Jong, A.
(1996) Interaction between yeast Cdc6 protein and B-type cyclin/
Cdc28 kinases. Mol. Biol. Cell. 7, 1723–1735.
[29] Aguanno, S., Bouche, M., Adamo, S. and Molinaro, M. (1990)
12-O-tetradecanoylphorbol-13-acetate-induced diﬀerentiation of
a human rhabdomyosarcoma cell line. Cancer Res. 50, 3377–
3382.
[30] Bouche, M., Senni, M.I., Grossi, A.M., Zappelli, F., Polimeni,
M., Arnold, H.H., Cossu, G. and Molinaro, M. (1993) TPA-
induced diﬀerentiation of human rhabdomyosarcoma cells:
expression of the myogenic regulatory factors. Exp. Cell Res.
208, 209–217.
[31] Benoit, G.R., Flexor, M., Besancon, F., Altucci, L., Rossin, A.,
Hillion, J., Balajthy, Z., Legres, L., Segal-Bendirdjian, E.,
Gronemeyer, H. and Lanotte, M. (2001) Autonomous rexinoid
death signaling is suppressed by converging signaling pathways in
immature leukemia cells. Mol. Endocrinol. 15, 1154–1169.
[32] Wyllie, A.H., Morris, R.G., Smith, A.L. and Dunlop, D. (1984)
Chromatin cleavage in apoptosis: association with condensed
chromatin morphology and dependence on macromolecular
synthesis. J. Pathol. 142, 67–77.
[33] Compton, M.M. (1992) A biochemical hallmark of apoptosis:
internucleosomal degradation of the genome. Cancer Metast.
Rev. 11, 105–119.
[34] Kopf, E., Plassat, J.L., Vivat, V., de The, H., Chambon, P. and
Rochette-Egly, C. (2000) Dimerization with retinoid X recep-
tors and phosphorylation modulate the retinoic acid-induced
degradation of retinoic acid receptors alpha and gamma
through the ubiquitin-proteasome pathway. J. Biol. Chem.
275, 33280–33288.
[35] Tanaka, T., Rodriguez de la Concepcion, M.L. and De Luca,
L.M. (2001) Involvement of all-trans-retinoic acid in the break-
down of retinoic acid receptors alpha and gamma through
G.C. Bao et al. / FEBS Letters 580 (2006) 3687–3693 3693proteasomes in MCF-7 human breast cancer cells. Biochem.
Pharmacol. 61, 1347–1355.
[36] el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons,
R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W. and
Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor
suppression. Cell 75, 817–825.
[37] Levine, A.J. (1997) p53, the cellular gatekeeper for growth and
division. Cell 88, 323–331.
[38] Cox, L.S. (1997) Multiple pathways control cell growth and
transformation: overlapping and independent activities of p53
and p21Cip1/WAF1/Sdi1. J. Pathol. 183, 134–140.
[39] Filippini, G., Balmelli, T., Eppenberger, H. and Soldati, G. (1999)
Flow cytometric detection of p53 protein after incubation of a
pre-B cell line with antitumor agents. Cytometry 35, 267–273.
[40] Roninson, I.B. (2002) Oncogenic functions of tumour suppressor
p21(Waf1/Cip1/Sdi1): association with cell senescence and tu-
mour-promoting activities of stromal ﬁbroblasts. Cancer Lett.
179, 1–14.
[41] Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K.,
Fukumuro, K. and Mizutani, S. (1999) Apoptosis inhibitory
activity of cytoplasmic p21(Cip1/WAF1) in monocytic diﬀerenti-
ation. EMBO J. 18, 1223–1234.
[42] Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T. and Miura, M.
(1998) Resistance to Fas-mediated apoptosis: activation of
caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP
gene family ILP. Oncogene 17, 931–939.
[43] Meikrantz, W., Gisselbrecht, S., Tam, S.W. and Schlegel, R.
(1994) Activation of cyclin A-dependent protein kinases during
apoptosis. Proc. Natl. Acad. Sci. USA 91, 3754–3758.
[44] Hoang, A.T., Cohen, K.J., Barrett, J.F., Bergstrom, D.A. and
Dang, C.V. (1994) Participation of cyclin A in Myc-induced
apoptosis. Proc. Natl. Acad. Sci. USA 91, 6875–6879.
[45] Polyak, K., Lee, M.H., Erdjument-Bromage, H., Koﬀ, A.,
Roberts, J.M., Tempst, P. and Massague, J. (1994) Cloning
of p27Kip1, a cyclin-dependent kinase inhibitor and apotential mediator of extracellular antimitogenic signals. Cell
78, 59–66.
[46] Toyoshima, H. and Hunter, T. (1994) p27, a novel inhibitor of G1
cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67–74.
[47] Lin, R.J., Sternsdorf, T., Tini, M. and Evans, R.M. (2001)
Transcriptional regulation in acute promyelocytic leukemia.
Oncogene 20, 7204–7215.
[48] Dilworth, F.J. and Chambon, P. (2001) Nuclear receptors
coordinate the activities of chromatin remodeling complexes
and coactivators to facilitate initiation of transcription. Oncogene
20, 3047–3054.
[49] Glass, C.K. and Rosenfeld, M.G. (2000) The coregulator
exchange in transcriptional functions of nuclear receptors. Genes
Dev. 14, 121–141.
[50] Aranda, A. and Pascual, A. (2001) Nuclear hormone receptors
and gene expression. Physiol. Rev. 81, 1269–1304.
[51] Rosenauer, A., Raelson, J.V., Nervi, C., Eydoux, P., DeBlasio, A.
and Miller Jr., W.H. (1996) Alterations in expression, binding to
ligand and DNA, and transcriptional activity of rearranged and
wild-type retinoid receptors in retinoid-resistant acute promyelo-
cytic leukemia cell lines. Blood 88, 2671–2682.
[52] Kinjo, K., Miyakawa, Y., Uchida, H., Kitajima, S., Ikeda, Y. and
Kizaki, M. (2004) All-trans retinoic acid directly up-regulates
thrombopoietin transcription in human bone marrow stromal
cells. Exp. Hematol. 32, 45–51.
[53] Jiang, H., Lin, J., Su, Z.Z., Collart, F.R., Huberman, E. and
Fisher, P.B. (1994) Induction of diﬀerentiation in human promy-
elocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expres-
sion in the absence of p53. Oncogene 9, 3397–3406.
[54] Casini, T. and Pelicci, P.G. (1999) A function of p21 during
promyelocytic leukemia cell diﬀerentiation independent of CDK
inhibition and cell cycle arrest. Oncogene 18, 3235–3243.
[55] Dimberg, A. and Oberg, F. (2003) Retinoic acid-induced cell cycle
arrest of human myeloid cell lines. Leuk. Lymphoma 44, 1641–
1650.
